Losartan Potassium Capsules

This product is an angiotensin II receptor (AT1 type antagonist. It can block the various pharmacological effects of endogenous and exogenous angiotensin II (including vasoconstriction, aldosterone release, etc.); this product can selectively act on AT1 receptors, does not affect the functions of other hormone receptors or important ion channels in the cardiovascular system, does not inhibit angiotensin converting enzyme (kininase II) that degrades bradykinin, and does not affect the metabolic process of angiotensin II and bradykinin. The LD50 of losartan potassium in male mice taken orally is 2248mg/Kg (67 44mg/m2) (1124 times the recommended maximum daily dose for adults). The significant minimum lethal doses for oral administration of this product to mice and rats were 1000mg/Kg (3000mg/m2) and 2000mg/Kg (11800mg/m2), respectively, which are 500 times and 1000 times the recommended maximum daily dose for adults, respectively*. The potential toxicity of losartan potassium was evaluated by a series of toxicity tests with multiple oral administrations for three months in monkeys and one year in rats and dogs. No obstruction to medication at therapeutic dose levels was found.

Losartan potassium. Chemical name: 2-butyl-4-chloro-1-[[2-(1H-tetrazolyl-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol monopotassium salt Molecular weight: C22H22ClKN6O

The content of this product is white or off-white granular powder.

This product is suitable for the treatment of hypertension.

For most patients, the usual starting and maintenance dose is 50 mg once a day. The maximum antihypertensive effect can be achieved after 3 to 6 weeks of treatment. In some patients, increasing the dose to 100 mg once a day can produce further antihypertensive effects. For patients with hypovolemia (such as patients treated with large doses of diuretics), a starting dose of 25 mg once a day should be considered (see Precautions). For elderly patients or patients with renal impairment, including those undergoing hemodialysis, there is no need to adjust the starting dose. For patients with a history of liver damage, a lower dose should be considered (see Precautions). This product can be used together with other antihypertensive drugs. This product can be taken with or without food.

This product is well tolerated, and the incidence of adverse reactions is similar to that of placebo. Adverse reactions are usually mild and transient, and generally do not require discontinuation of treatment.

It is contraindicated for those who are allergic to any ingredient of this product.

Precautions for children: There is no safety and efficacy data for children. Precautions for pregnancy and lactation: This drug is not recommended. Precautions for the elderly: There is no significant difference in the efficacy and safety of this drug in the elderly and adults.

Like other drugs that block angiotensin II and its effects, this product can cause increased serum potassium when used with potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes. Like other antihypertensive drugs, the nonsteroidal anti-inflammatory drug indomethacin can reduce the antihypertensive effect of losartan.

Store in a cool, dry place.

100mg

24 months

Beijing Foyou Pharma Co., Ltd.

• Founded in:

  1999-02-03

• Address:

  No. 8 Guangyuan East Street, Tongzhou Industrial Development Zone, Tongzhou District, Beijing

• Tax NO.:

  91110112700216160K

• Registered Funds:

  480 million yuan

• Website:

  Log in to view

• Email:

  Log in to view